[Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].
An early phase II clinical study was done to investigate the activity and the safety of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer. An interim analysis was done after registration of 24 cases. One case was a dropout because of an insufficient administration period (4 days). The other 23 cases were complete: they comprised 9 cases of adenocarcinoma, 13 cases of squamous cell carcinoma, and 1 case of large cell carcinoma. Prior therapy had not been given in two cases. The doses used were 50 mg/person/day in 12 cases and 75 mg/person/day in 11 cases. The response observed was one case of at 50 mg/person/day to stage IV squamous cell carcinoma, 17 cases were no change, 5 cases were progressing disease, and giving a response rate of 4.3% in complete cases. Considering those results, we decided that it would be difficult to achieve a 20% response rate by the end of this study, and therefore the study was terminated. The side effects of the regimen were tolerable. In conclusion, etoposide was not active against non-small-cell lung cancer at the dosage and schedule employed. Further investigation is required to obtain a more effective form of therapy.
Hayasaka
S
S
Kinuwaki
E
E
Nakabayashi
T
T
Saito
R
R
Komatsu
H
H
Nishikawa
H
H
Ohizumi
K
K
Shimizu
T
T
Nakai
Y
Y
Niitani
H
H
D000230:Adenocarcinoma / Q000188:drug therapy; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide